Immunomedics Inc. (NASDAQ:IMMU) – Equities research analysts at Jefferies Group issued their Q2 2017 earnings estimates for Immunomedics in a research report issued on Thursday. Jefferies Group analyst M. Andrews anticipates that the firm will post earnings per share of ($0.09) for the quarter. Jefferies Group has a “Buy” rating and a $5.50 price target on the stock. Jefferies Group also issued estimates for Immunomedics’ Q3 2017 earnings at ($0.08) EPS, Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.35) EPS, FY2018 earnings at ($0.17) EPS, FY2019 earnings at $0.08 EPS and FY2020 earnings at $0.23 EPS.
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.06.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded Immunomedics from a “strong sell” rating to a “hold” rating and set a $2.75 price target for the company in a research note on Friday, October 7th. Wells Fargo & Co. downgraded Immunomedics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 21st.
Shares of Immunomedics (NASDAQ:IMMU) traded up 1.1360% during midday trading on Monday, hitting $2.5284. The company had a trading volume of 265,404 shares. The stock’s market capitalization is $242.39 million. Immunomedics has a one year low of $1.61 and a one year high of $5.44. The stock’s 50-day moving average price is $2.96 and its 200-day moving average price is $3.04.
Several institutional investors have recently made changes to their positions in IMMU. Sabby Management LLC bought a new stake in Immunomedics during the first quarter worth approximately $182,240,000. venBio Select Advisor LLC bought a new stake in Immunomedics during the first quarter worth approximately $2,626,000. Opaleye Management Inc. boosted its stake in Immunomedics by 356.9% in the first quarter. Opaleye Management Inc. now owns 1,325,000 shares of the biopharmaceutical company’s stock worth $3,313,000 after buying an additional 1,035,000 shares during the period. State Street Corp boosted its stake in Immunomedics by 63.3% in the second quarter. State Street Corp now owns 2,354,732 shares of the biopharmaceutical company’s stock worth $5,463,000 after buying an additional 912,372 shares during the period. Finally, Iguana Healthcare Management LLC bought a new stake in Immunomedics during the second quarter worth approximately $522,000. Hedge funds and other institutional investors own 53.79% of the company’s stock.
In other news, Director Don C. Stark sold 9,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $2.97, for a total value of $29,403.00. Following the transaction, the director now owns 55,848 shares in the company, valued at approximately $165,868.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mary E. Paetzold sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $2.98, for a total value of $44,700.00. Following the completion of the transaction, the director now owns 82,474 shares in the company, valued at approximately $245,772.52. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.
Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.